Neuroprotective effect of early and short-time applying sophoridine in pMCAO rat brain: Down-regulated TRAF6 and up-regulated p-ERK1/2 expression, ameliorated brain infaction and edema

Brain Research Bulletin

Volumn 88, Issue 4, 2012, Pages 379-384

  Liu, Zongjie ^a   He, Dan ^a   Zhang, Xiangjian ^a,b,c   Li, Yanhua ^a   Zhu, Chunhua ^a   Dong, Lipeng ^a   Zhang, Xiaolin ^a   Xing, Yinxue ^a   Wang, Chaohui ^a   Qiao, Huimin ^a   Chen, Linyu ^a  

^a HEBEI MEDICAL UNIVERSITY   (China)

^b Hebei Institute of Cardio Cerebral Vascular Diseases   (China)

^c Hebei Key Laboratory for Neurology   (China)

Author keywords

Cerebral ischemia; ERK1 2; Middle cerebral artery occlusion; Sophoridine; TRAF6

Indexed keywords

MATRINE; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; SOPHORIDINE; TUMOR NECROSIS FACTOR RECEPTOR ASSOCIATED FACTOR 6; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRAIN EDEMA; BRAIN INFARCTION; BRAIN INFARCTION SIZE; BRAIN WATER; CONTROLLED STUDY; DRUG MEGADOSE; DRUG STRUCTURE; ENZYME PHOSPHORYLATION; IMMUNOHISTOCHEMISTRY; LOW DRUG DOSE; MALE; MIDDLE CEREBRAL ARTERY OCCLUSION; NEUROPROTECTION; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; WESTERN BLOTTING;

ALKALOIDS; ANIMALS; BLOTTING, WESTERN; BRAIN; BRAIN EDEMA; DOWN-REGULATION; IMMUNOHISTOCHEMISTRY; INFARCTION, MIDDLE CEREBRAL ARTERY; MALE; MITOGEN-ACTIVATED PROTEIN KINASE 1; MITOGEN-ACTIVATED PROTEIN KINASE 3; NEUROPROTECTIVE AGENTS; QUINOLIZINES; RATS; RATS, SPRAGUE-DAWLEY; TNF RECEPTOR-ASSOCIATED FACTOR 6; UP-REGULATION;

EID: 84862171392     PISSN: 03619230     EISSN: 18732747     Source Type: Journal    
DOI: 10.1016/j.brainresbull.2012.04.003     Document Type: Article

References (39)

1. Ali S., Mann D.A. Signal transduction via the NF-kappaB pathway: a targeted treatment modality for infection, inflammation and repair. Cell Biochem. Funct. 2004, 22:67-279.
2. Allan S.M., Rothwell N.J. Cytokines and acute neurodegeneration. Nat. Rev. Neurosci. 2001, 2:734-744.
3. Barone F.C., Arvin B., White R.F., Miller A., Webb C.L., Willette R.N., Lysko P.G., Feuerstein G.Z. Tumor necrosis factor-alpha, a mediator of focal ischemic brain injury. Stroke 1997, 28:1233-1244.
4. Barton G.M., Medzhitov R. Toll-like receptor signaling pathways. Science 2003, 300:1524-1525.
5. Bluhmki E., Chamorro A., Dávalos A., Machnig T., Sauce C., Wahlgren N., Wardlaw J., Hacke W. Stroke treatment with alteplase given 3. 0-4.5h after onset of acute ischaemic stroke (ECASS III): additional outcomes and subgroup analysis of a randomised controlled trial. Lancet Neurol. 2009, 8:1095-1102.
6. Bradley J.R., Pober J.S. Tumor necrosis factor receptor associated factors (TRAFs). Oncogene 2001, 20:6482-6491.
7. Chantzoura E., Prinarakis E., Panagopoulos D., Mosialos G., Spyrou G. Glutaredoxin-1 regulates TRAF6 activation and the IL-1 receptor/TLR4 signalling. Biochem. Biophys. Res. Commun. 2010, 403:335-339.
8. Chen L., Wang F., Han Z. Effects of matrine on inflammatory cytokines for rats with cerebral ischemia reperfusion injury. JETCM 2010, 19:2098-2099.
9. Chen J., Wu X., Shao B., Zhao W., Shi W., Zhang S., Ni L., Shen A. Increased expression of TNF receptor-associated factor 6 after rat traumatic brain injury. Cell. Mol. Neurobiol. 2011, 31:269-275.
10. Cui L., Zhang X., Yang R., Wang L., Liu L., Li M., Du W. Neuroprotection and underlying mechanisms of oxymatrine in cerebral ischemia of rats. Neurol. Res. 2011, 33:319-324.
11. Das A., Salloum F.N., Xi L., Rao Y.J., Kukreja R.C. ERK phosphorylation mediates sildenafil-induced myocardial protection against ischemia-reperfusion injury in mice. Am. J. Physiol. Heart Circ. Physiol. 2009, 296:H1236-H1243.
12. Ding Y., Li J., Rafols J.A., Phillis J.W., Diaz F.G. Pre-reperfusion saline infusion into ischemic territory reduces inflammatory injury after transient middle cerebral artery occlusion in rats. Stroke 2002, 33:2492-2498.
13. Emsley H.C., Tyrrell P.J. Inflammation and infection in clinical stroke. J. Cereb. Blood Flow Metab. 2002, 22:1399-1419.
14. Gesslein B., Hakansson G., Gustafsson L., Ekstrom P., Malmsjo M. Tumor necrosis factor and its receptors in the neuroretina and retinal vasculature after ischemia-reperfusion injury in the pig retina. Mol. Vis. 2010, 16:2317-2327.
15. Huang J., Upadhyay U.M., Tamargo R.J. Inflammation in stroke and focal cerebral ischemia. Surg. Neurol. 2006, 66:232-245.
16. Ji H., Miao J., Zhang X., Du Y., Liu H., Li S., Li L. Inhibition of sonic hedgehog signaling aggravates brain damage associated with the down-regulation of Gli1, Ptch1 and SOD1 expression in acute ischemic stroke. Neurosci. Lett. 2012, 506:1-6.
17. Kashiwada M., Shirakata Y., Inoue J.I., Nakano H., Okazaki K., Okumura K., Yamamoto T., Nagaoka H., Takemori T. Tumor necrosis factor receptor-associated factor 6 (TRAF6) stimulates extracellular signal-regulated kinase (ERK) activity in CD40 signaling along a ras-independent pathway. J. Exp. Med. 1998, 187:237-244.
18. Lansberg M.G., Bluhmk E., Thijs V.N. Efficacy and safety of tissue plasminogen activator 3 to 4.5h after acute ischemic stroke: a metaanalysis. Stroke 2009, 40:2438-2441.
19. Li X., Chu W., Liu J., Xue X., Lu Y., Shan H., Yang B. Antiarrhythmic properties of long-term treatment with matrine in arrhythmic rat induced by coronary ligation. Biol. Pharm. Bull. 2009, 32:1521-1526.
20. Li M., Zhang X., Cui L., Yang R., Wang L., Liu L., Du W. The neuroprotection of oxymatrine in cerebral ischemia/reperfusion is related to nuclear factor erythroid 2-related factor 2 (Nrf2)-mediated antioxidant response: role of Nrf2 and hemeoxygenase-1 expression. Biol. Pharm. Bull. 2011, 34:595-601.
21. Liu T., Clark R.K., McDonnell P.C., Young P.R., White R.F., Barone F.C., Feuerstein G.Z. Tumor necrosis factor-alpha expression in ischemic neurons. Stroke 1994, 25:1481-1488.
22. Liu M., Liu X.Y., Cheng J.F. Advance in the pharmacological research on matrine. Zhongguo Zhong Yao Za Zhi 2003, 28:801-804.
23. Liu Y., Zhang X.J., Yang C.H., Fan H.G. Oxymatrine protects rat brains against permanent focal ischemia and downregulates NF-κB expression. Brain Res. 2009, 1268:174-180.
24. Lloyd-Jones D., Adams R.J., Brown T.M., Carnethon M., Dai S., De Simone G., Ferguson T.B., Ford E., Furie K., Gillespie C., Go A., Greenlund K., Haase N., Hailpern S., Ho P.M., Howard V., Kissela B., Kittner S., Lackland D., Lisabeth L., Marelli A., McDermott M.M., Meigs J., Mozaffarian D., Mussolino M., Nichol G., Roger V.L., Rosamond W., Sacco R., Sorlie P., Stafford R., Thom T., Wasserthiel-Smoller S., Wong N.D., Wylie-Rosett J. Executive summary: heart disease and stroke statistics-2010 update: a report from the American Heart Association. Circulation 2010, 121:948-954.
25. Longa E.Z., Weinstein P.R., Carlson S., Cummins R. Reversible middle cerebral artery occlusion without craniotomy in rats. Stroke 1989, 20:84-91.
26. Maddahi A., Kruse L.S., Chen Q.W., Edvinsson L. The role of tumor necrosis factor-a and TNF-a receptors in cerebral arteries following cerebral ischemia in rat. J. Neuroinflammation 2011, 8:107.
27. Miyahara T., Koyama H., Miyata T., Shigematsu H., Inoue J., Takato T., Nagawa H. Inflammatory signaling pathway containing TRAF6 contributes to neointimal formation via diverse mechanisms. Cardiovasc. Res. 2004, 64:154-164.
28. Mukundan L., Bishop G.A., Head K.Z., Zhang L., Wahl L.M., Suttles J. TNF receptor-associated factor 6 is an essential mediator of CD40-activated pro-inflammatory pathways in monocytes and macrophages. J. Immunol. 2005, 174:1081-1090.
29. O'Collins V.E., Macleod M.R., Donnan G.A., Horky L.L., Worp B.H., Howells D.W. 1,026 experimental treatments in acute stroke. Ann. Neurol. 2006, 59:467-477.
30. Ross A.M., Hurn P., Perrin N., Wood L., Carlini W., Potempa K. Evidence of the peripheral inflammatory response in patients with transient ischemic attack. J. Stroke Cerebrovasc. Dis. 2007, 16:203-207.
31. Tatlisumak T., Carano R.A., Takano K., Opgenorth T.J., Sotak C.H., Fisher M. A novel endothelin antagonist, A-127722, attenuates ischemic lesion size in rats with temporary middle cerebral artery occlusion: a diffusion and perfusion MRI study. Stroke 1998, 29:850-857.
32. Thompson W.L., Van Eldik L.J. Inflammatory cytokines stimulate the chemokines CCL2/MCP-1 and CCL7/MCP-7 through NFkappaB and MAPK dependent pathways in rat astrocytes. Brain Res. 2009, 1287:47-57.
33. Wu H., Arron J.R. TRAF6, a molecular bridge spanning adaptive immunity, innate immunity and osteoimmunology. Bioessays 2003, 25:1096-1105.
34. Xu R., Chen J., Cong X., Hu S., Chen X. Lovastatin protects mesenchymal stem cells against hypoxia- and serum deprivation-induced apoptosis by activation of PI3K/Akt and ERK1/2. J. Cell Biochem. 2008, 103:256-269.
35. Yang C., Zhang X., Fan H., Liu Y. Curcumin upregulates transcription factor Nrf2, HO-1 expression and protects rat brains against focal ischemia. Brain Res. 2009, 1282:133-141.
36. Zhang Y., Zhu H., Ye G., Huang C., Yang Y., Chen R., Yu Y., Cui X. Antiviral effects of sophoridine against coxsackievirus B3 and its pharmacokinetics in rats. Life Sci. 2006, 78:1998-2005.
37. + channel. Eur. J. Pharmacol. 2009, 607:15-22.
38. Zhu X.H., Qiu Y.D., Shen H., Shi M.K., Ding Y.T. Effect of matrine on Kupffer cell activation in cold ischemia reperfusion injury of rat liver. World J. Gastroenterol. 2002, 8:1112-1116.
39. Zucchelli S., Marcuzzi F., Codrich M., Agostoni E., Vilotti S., Biagioli M., Pinto M., Carnemolla A., Santoro C., Gustincich S., Persichetti F. Tumor necrosis factor receptor-associated factor 6 (TRAF6) associates with huntingtin protein and promotes its atypical ubiquitination to enhance aggregate formation. J. Biol. Chem. 2011, 286:25108-25117.